| Xlife Sciences AG appoints new Chief Financial Officer DGAP Press release December 1, 2021 Media release Xlife Sciences appoints new Chief Financial Officer Xlife Sciences (XLS DE) announced that Carl von Halem has been appointed as the Company's new Chief Financial Officer, effective as of today, 1 December 2021. Beat Kläui, who has been interim CFO since January 2019, will continue to serve Xlife Sciences as Head Accounting & Tax. Carl von Halem has been Co-Founder and Chief Operating Officer of the Munich-based FinTech company CommneX since September 2016. CommneX's digital tendering and matchmaking platform brings together financial projects of municipalities, public corporations and municipal-related companies with financial partners such as banks, insurance companies and institutional investors. Previously, Carl worked, among others, as Senior Associate for the Berlin-based company SaEnergy Systems, which is active in the field of renewable energies. He holds a degree in economics from the Technical University of Berlin; as part of his studies, he completed an exchange semester at Udayana University Denpasar, Indonesia and a summer school in «Environmental Economics» at the London School of Economics. Oliver R. Baumann, CEO of Xlife Sciences, commented: «With his international education, various stations in the fast-paced and challenging startup environment, the necessary leadership experience and his impressive work ethic, Carl brings the necessary skills to actively support our team and further advance the vision of Xlife Sciences. At the same time, we sincerely thank Beat for his valuable support in the last three years and are very happy that we are able to continue to rely on his wealth of experience.» About Xlife Sciences Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life Contact For media inquiries: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch For investor inquiries: Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Phone +41 44 385 84 60, dennis.lennartz@xlifesciences.ch
Issuer: Xlife Sciences AG 01.12.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|
| Language: |
English |
| Company: |
Xlife Sciences AG |
| |
Talacker 35 |
| |
8001 Zürich |
| |
Switzerland |
| Phone: |
0041 44 385 84 60 |
| E-mail: |
info@xlifesciences.ch |
| Internet: |
www.xlifesciences.ch |
| ISIN: |
CH0461929603 |
| WKN: |
A2PK6Z |
| Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: |
1253111 |
| |
| |
|
| End of News |
DGAP Media |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.